Inozyme Pharma Inc. (INZY)
1.20
0.00 (0.00%)
At close: Mar 03, 2025, 12:37 PM
Inozyme Pharma Balance Sheet Statement
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
Cash & Equivalents | 34.59M | 32.91M | 23.32M | 159.9M | 31.61M | 35.97M |
Short-Term Investments | 154M | 94.95M | 88.48M | 119.66M | 15.53M | 7.2M |
Long-Term Investments | n/a | 354K | 354K | 12.2M | 130K | n/a |
Other Long-Term Assets | 2M | 3.81M | 3.41M | 3.54M | 56K | 34K |
Receivables | 385K | 115K | 62K | 155K | 104K | 31K |
Inventory | n/a | -115K | -62K | -12.35M | n/a | n/a |
Other Current Assets | 7.28M | 3.41M | 3.48M | 3.12M | 190K | 73K |
Total Current Assets | 196.25M | 131.39M | 115.34M | 150.98M | 47.46M | 43.27M |
Property-Plant & Equipment | 2.59M | 3.64M | 4.44M | 2.65M | 298K | 242K |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 4.6M | 7.8M | 8.2M | 18.38M | 484K | 276K |
Total Assets | 200.85M | 139.19M | 123.54M | 169.36M | 47.94M | 43.54M |
Account Payables | 1.17M | 2.54M | 2.39M | 3.07M | 901K | 984K |
Deferred Revenue | n/a | 3.81M | n/a | 279K | n/a | n/a |
Short-Term Debt | 910K | 1.63M | 1.46M | n/a | n/a | n/a |
Other Current Liabilities | 12.61M | 10.54M | 7.78M | 6.9M | 2.33M | 1.41M |
Total Current Liabilities | 14.69M | 14.71M | 11.63M | 9.97M | 3.24M | 2.39M |
Long-Term Debt | 45.68M | 5.96M | 2.64M | 1.29M | n/a | n/a |
Other Long-Term Liabilities | n/a | 124K | n/a | n/a | n/a | 55.03M |
Total Long-Term Liabilities | 45.68M | 6.09M | 2.64M | 1.29M | 77.93M | 55.03M |
Total Liabilities | 60.37M | 20.8M | 14.27M | 11.26M | 81.16M | 57.42M |
Total Debt | 46.59M | 6.78M | 3.37M | 1.29M | n/a | n/a |
Common Stock | 6K | 4K | 2K | 2K | 1K | 1K |
Retained Earnings | -285.93M | -214.76M | -147.7M | -91.08M | -34.65M | -14.93M |
Comprehensive Income | 41K | -205K | 18K | 2K | 5K | -2K |
Shareholders Equity | 140.48M | 118.59M | 109.27M | 158.1M | -33.22M | -13.88M |
Total Investments | 154M | 94.95M | 88.48M | 131.86M | 15.53M | 7.2M |